Global Autoimmune Disease Therapeutics
Global Autoimmune Disease Therapeutics

Autoimmune Disease Therapeutics Comprehensive Study by Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Others), Distribution Channel (Hospitals, Clinics, Drug Stores, Independent pharmacies), Drug Class (Immunosuppressants, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs, Biologics, Others) Players and Region - Global Market Outlook to 2026

Autoimmune Disease Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026 | CAGR: 3.92%  

Jan 2021 Edition 202 Pages 190 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Autoimmune diseases are more commonly caused by genetic, infectious, or environmental factors. Autoimmune disease (AD) is one of the emerging non-communicable diseases. According to the National Institute of Health, approximately 50 million Americans suffer from autoimmune diseases. The disease is estimated to be one of the top 10 causes of death in women under the age of 65 and is the second-highest cause of chronic illness. Also, it is the top cause of morbidity in women in the United States. This is accelerating the growth of the global autoimmune disease therapeutics market. Rising prevalence of autoimmune diseases the demand for drugs used in the treatment for autoimmune disease is also growing and it has projected the growth of the autoimmune disease therapeutics market in the forecast period.According to AMA, the market for Autoimmune Disease Therapeutics is expected to register a CAGR of 3.92% during the forecast period to 2026. This growth is primarily driven by Growing Prevalence of Autoimmune Diseases Coupled With Growing Public Awareness and Presence of Government Initiatives Such As Affordable Care Act and Patient Protection Act.

Globally, a noticeable market trend is evident Increasing Automation of Laboratories Leading to Diagnosis of Several Diagnostic Tests Simultaneously to Generate Rapid and Error Free Results. Major Players, such as Abbott Laboratories (United States), Amgen Inc. (United States), Genentech Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (United States), Novartis International AG (Switzerland), Merck & Co. Inc. (United States), Bayer Schering Pharma AG (Germany), Johnson & Johnson Inc. (United States), Parvus Therapeutics Inc (United States), Biogen Idec Inc. (United States) and Sanofi S.A (France) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 17th August 2020, Sanofi and Principia Biopharma Inc. a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi has acquired all of the outstanding shares of Principia for USD 100 per share in cash, which represents an aggregate equity value of approximately USD 3.68 billion.
On 26th June 2019, Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune diseases without impairing normal immunity, has announced a license and collaboration agreement to develop Navacim therapeutics for gastrointestinal inflammatory diseases, including autoimmune liver diseases (ALD).

Market Drivers
  • Growing Prevalence of Autoimmune Diseases Coupled With Growing Public Awareness
  • Presence of Government Initiatives Such As Affordable Care Act and Patient Protection Act

Market Trend
  • Increasing Automation of Laboratories Leading to Diagnosis of Several Diagnostic Tests Simultaneously to Generate Rapid and Error Free Results

Restraints
  • Inadequate Funding in Developing Countries
  • High Cost Involved in the Treatment of the Disease

Opportunities
Technological Advancements such as the Development of Novel Biomarkers such as Enbrel and Humira, and Portable Diagnostic Point of Care Equipment
Challenges
Non-Availability of the Treatment in Developing Countries along with Emergence of Alternative Technologies

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
AMA Research & Media features not only specific market forecasts, but also include significant value-added commentary on:
Market Trends
Technological Trends and Innovations
Regulatory Trends & Policies
Market Maturity Indicators
Market Share Movements
Growth Drivers and Constraints
New Entrants into the Market & Entry/Exit Barriers
Consumer Demographics
Supporting Company Financial and Cash Flow Planning
Open Up New Markets
To Seize Powerful Market Opportunities
Key Decision in Planning and to Further Expand Market Share
Identify Key Business Segments, Market Proposition & Gap Analysis
Report Objectives / Segmentation Covered
By Indication
  • Rheumatic Disease
  • Type 1 Diabetes
  • Multiple Sclerosis
  • Inflammatory Bowel Disease
  • Others

By Distribution Channel
  • Hospitals
  • Clinics
  • Drug Stores
  • Independent pharmacies

By Drug Class
  • Immunosuppressants
  • Anti-Inflammatory Drugs
  • Corticosteroids
  • Nonsteroidal Anti-inflammatory Drugs
  • Biologics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Autoimmune Diseases Coupled With Growing Public Awareness
      • 3.2.2. Presence of Government Initiatives Such As Affordable Care Act and Patient Protection Act
    • 3.3. Market Challenges
      • 3.3.1. Non-Availability of the Treatment in Developing Countries along with Emergence of Alternative Technologies
    • 3.4. Market Trends
      • 3.4.1. Increasing Automation of Laboratories Leading to Diagnosis of Several Diagnostic Tests Simultaneously to Generate Rapid and Error Free Results
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Autoimmune Disease Therapeutics, by Indication, Distribution Channel, Drug Class and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Autoimmune Disease Therapeutics (Value)
      • 5.2.1. Global Autoimmune Disease Therapeutics by: Indication (Value)
        • 5.2.1.1. Rheumatic Disease
        • 5.2.1.2. Type 1 Diabetes
        • 5.2.1.3. Multiple Sclerosis
        • 5.2.1.4. Inflammatory Bowel Disease
        • 5.2.1.5. Others
      • 5.2.2. Global Autoimmune Disease Therapeutics by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Drug Stores
        • 5.2.2.4. Independent pharmacies
      • 5.2.3. Global Autoimmune Disease Therapeutics by: Drug Class (Value)
        • 5.2.3.1. Immunosuppressants
        • 5.2.3.2. Anti-Inflammatory Drugs
        • 5.2.3.3. Corticosteroids
        • 5.2.3.4. Nonsteroidal Anti-inflammatory Drugs
        • 5.2.3.5. Biologics
        • 5.2.3.6. Others
      • 5.2.4. Global Autoimmune Disease Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Autoimmune Disease Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Genentech Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer Schering Pharma AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Parvus Therapeutics Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Biogen Idec Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sanofi S.A (France)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Autoimmune Disease Therapeutics Sale, by Indication, Distribution Channel, Drug Class and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Autoimmune Disease Therapeutics (Value)
      • 7.2.1. Global Autoimmune Disease Therapeutics by: Indication (Value)
        • 7.2.1.1. Rheumatic Disease
        • 7.2.1.2. Type 1 Diabetes
        • 7.2.1.3. Multiple Sclerosis
        • 7.2.1.4. Inflammatory Bowel Disease
        • 7.2.1.5. Others
      • 7.2.2. Global Autoimmune Disease Therapeutics by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Drug Stores
        • 7.2.2.4. Independent pharmacies
      • 7.2.3. Global Autoimmune Disease Therapeutics by: Drug Class (Value)
        • 7.2.3.1. Immunosuppressants
        • 7.2.3.2. Anti-Inflammatory Drugs
        • 7.2.3.3. Corticosteroids
        • 7.2.3.4. Nonsteroidal Anti-inflammatory Drugs
        • 7.2.3.5. Biologics
        • 7.2.3.6. Others
      • 7.2.4. Global Autoimmune Disease Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Autoimmune Disease Therapeutics: by Indication(USD Million)
  • Table 2. Autoimmune Disease Therapeutics Rheumatic Disease , by Region USD Million (2015-2020)
  • Table 3. Autoimmune Disease Therapeutics Type 1 Diabetes , by Region USD Million (2015-2020)
  • Table 4. Autoimmune Disease Therapeutics Multiple Sclerosis , by Region USD Million (2015-2020)
  • Table 5. Autoimmune Disease Therapeutics Inflammatory Bowel Disease , by Region USD Million (2015-2020)
  • Table 6. Autoimmune Disease Therapeutics Others , by Region USD Million (2015-2020)
  • Table 7. Autoimmune Disease Therapeutics: by Distribution Channel(USD Million)
  • Table 8. Autoimmune Disease Therapeutics Hospitals , by Region USD Million (2015-2020)
  • Table 9. Autoimmune Disease Therapeutics Clinics , by Region USD Million (2015-2020)
  • Table 10. Autoimmune Disease Therapeutics Drug Stores , by Region USD Million (2015-2020)
  • Table 11. Autoimmune Disease Therapeutics Independent pharmacies , by Region USD Million (2015-2020)
  • Table 12. Autoimmune Disease Therapeutics: by Drug Class(USD Million)
  • Table 13. Autoimmune Disease Therapeutics Immunosuppressants , by Region USD Million (2015-2020)
  • Table 14. Autoimmune Disease Therapeutics Anti-Inflammatory Drugs , by Region USD Million (2015-2020)
  • Table 15. Autoimmune Disease Therapeutics Corticosteroids , by Region USD Million (2015-2020)
  • Table 16. Autoimmune Disease Therapeutics Nonsteroidal Anti-inflammatory Drugs , by Region USD Million (2015-2020)
  • Table 17. Autoimmune Disease Therapeutics Biologics , by Region USD Million (2015-2020)
  • Table 18. Autoimmune Disease Therapeutics Others , by Region USD Million (2015-2020)
  • Table 19. South America Autoimmune Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 20. South America Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 21. South America Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 22. South America Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 23. Brazil Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 24. Brazil Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 25. Brazil Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 26. Argentina Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 27. Argentina Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 28. Argentina Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 29. Rest of South America Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 30. Rest of South America Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 31. Rest of South America Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 32. Asia Pacific Autoimmune Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 33. Asia Pacific Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 34. Asia Pacific Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 35. Asia Pacific Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 36. China Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 37. China Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 38. China Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 39. Japan Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 40. Japan Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 41. Japan Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 42. India Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 43. India Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 44. India Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 45. South Korea Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 46. South Korea Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 47. South Korea Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 48. Taiwan Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 49. Taiwan Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 50. Taiwan Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 51. Australia Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 52. Australia Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 53. Australia Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 57. Europe Autoimmune Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 58. Europe Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 59. Europe Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 60. Europe Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 61. Germany Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 62. Germany Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 63. Germany Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 64. France Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 65. France Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 66. France Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 67. Italy Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 68. Italy Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 69. Italy Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 70. United Kingdom Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 71. United Kingdom Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 72. United Kingdom Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 73. Netherlands Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 74. Netherlands Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 75. Netherlands Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 76. Rest of Europe Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 77. Rest of Europe Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 78. Rest of Europe Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 79. MEA Autoimmune Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 80. MEA Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 81. MEA Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 82. MEA Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 83. Middle East Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 84. Middle East Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 85. Middle East Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 86. Africa Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 87. Africa Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 88. Africa Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 89. North America Autoimmune Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 90. North America Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 91. North America Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 92. North America Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 93. United States Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 94. United States Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 95. United States Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 96. Canada Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 97. Canada Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 98. Canada Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 99. Mexico Autoimmune Disease Therapeutics, by Indication USD Million (2015-2020)
  • Table 100. Mexico Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 101. Mexico Autoimmune Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Autoimmune Disease Therapeutics: by Indication(USD Million)
  • Table 115. Autoimmune Disease Therapeutics Rheumatic Disease , by Region USD Million (2021-2026)
  • Table 116. Autoimmune Disease Therapeutics Type 1 Diabetes , by Region USD Million (2021-2026)
  • Table 117. Autoimmune Disease Therapeutics Multiple Sclerosis , by Region USD Million (2021-2026)
  • Table 118. Autoimmune Disease Therapeutics Inflammatory Bowel Disease , by Region USD Million (2021-2026)
  • Table 119. Autoimmune Disease Therapeutics Others , by Region USD Million (2021-2026)
  • Table 120. Autoimmune Disease Therapeutics: by Distribution Channel(USD Million)
  • Table 121. Autoimmune Disease Therapeutics Hospitals , by Region USD Million (2021-2026)
  • Table 122. Autoimmune Disease Therapeutics Clinics , by Region USD Million (2021-2026)
  • Table 123. Autoimmune Disease Therapeutics Drug Stores , by Region USD Million (2021-2026)
  • Table 124. Autoimmune Disease Therapeutics Independent pharmacies , by Region USD Million (2021-2026)
  • Table 125. Autoimmune Disease Therapeutics: by Drug Class(USD Million)
  • Table 126. Autoimmune Disease Therapeutics Immunosuppressants , by Region USD Million (2021-2026)
  • Table 127. Autoimmune Disease Therapeutics Anti-Inflammatory Drugs , by Region USD Million (2021-2026)
  • Table 128. Autoimmune Disease Therapeutics Corticosteroids , by Region USD Million (2021-2026)
  • Table 129. Autoimmune Disease Therapeutics Nonsteroidal Anti-inflammatory Drugs , by Region USD Million (2021-2026)
  • Table 130. Autoimmune Disease Therapeutics Biologics , by Region USD Million (2021-2026)
  • Table 131. Autoimmune Disease Therapeutics Others , by Region USD Million (2021-2026)
  • Table 132. South America Autoimmune Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 133. South America Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 134. South America Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 135. South America Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 136. Brazil Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 137. Brazil Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 138. Brazil Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 139. Argentina Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 140. Argentina Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 141. Argentina Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 142. Rest of South America Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 143. Rest of South America Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 144. Rest of South America Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 145. Asia Pacific Autoimmune Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 146. Asia Pacific Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 147. Asia Pacific Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 148. Asia Pacific Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 149. China Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 150. China Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 151. China Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 152. Japan Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 153. Japan Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 154. Japan Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 155. India Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 156. India Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 157. India Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 158. South Korea Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 159. South Korea Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 160. South Korea Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 161. Taiwan Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 162. Taiwan Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 163. Taiwan Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 164. Australia Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 165. Australia Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 166. Australia Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 167. Rest of Asia-Pacific Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 168. Rest of Asia-Pacific Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 169. Rest of Asia-Pacific Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 170. Europe Autoimmune Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 171. Europe Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 172. Europe Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 173. Europe Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 174. Germany Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 175. Germany Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 176. Germany Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 177. France Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 178. France Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 179. France Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 180. Italy Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 181. Italy Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 182. Italy Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 183. United Kingdom Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 184. United Kingdom Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 185. United Kingdom Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 186. Netherlands Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 187. Netherlands Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 188. Netherlands Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 189. Rest of Europe Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 190. Rest of Europe Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 191. Rest of Europe Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 192. MEA Autoimmune Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 193. MEA Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 194. MEA Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 195. MEA Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 196. Middle East Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 197. Middle East Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 198. Middle East Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 199. Africa Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 200. Africa Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 201. Africa Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 202. North America Autoimmune Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 203. North America Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 204. North America Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 205. North America Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 206. United States Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 207. United States Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 208. United States Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 209. Canada Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 210. Canada Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 211. Canada Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 212. Mexico Autoimmune Disease Therapeutics, by Indication USD Million (2021-2026)
  • Table 213. Mexico Autoimmune Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 214. Mexico Autoimmune Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 215. Research Programs/Design for This Report
  • Table 216. Key Data Information from Secondary Sources
  • Table 217. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Autoimmune Disease Therapeutics: by Indication USD Million (2015-2020)
  • Figure 5. Global Autoimmune Disease Therapeutics: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Autoimmune Disease Therapeutics: by Drug Class USD Million (2015-2020)
  • Figure 7. South America Autoimmune Disease Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Autoimmune Disease Therapeutics Share (%), by Country
  • Figure 9. Europe Autoimmune Disease Therapeutics Share (%), by Country
  • Figure 10. MEA Autoimmune Disease Therapeutics Share (%), by Country
  • Figure 11. North America Autoimmune Disease Therapeutics Share (%), by Country
  • Figure 12. Global Autoimmune Disease Therapeutics share by Players 2020 (%)
  • Figure 13. Global Autoimmune Disease Therapeutics share by Players (Top 3) 2020(%)
  • Figure 14. Global Autoimmune Disease Therapeutics share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 18. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Genentech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Genentech Inc. (United States) Revenue: by Geography 2020
  • Figure 22. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Merck & Co. Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Bayer Schering Pharma AG (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Bayer Schering Pharma AG (Germany) Revenue: by Geography 2020
  • Figure 32. Johnson & Johnson Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Johnson & Johnson Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Parvus Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 35. Parvus Therapeutics Inc (United States) Revenue: by Geography 2020
  • Figure 36. Biogen Idec Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Biogen Idec Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 39. Sanofi S.A (France) Revenue: by Geography 2020
  • Figure 40. Global Autoimmune Disease Therapeutics: by Indication USD Million (2021-2026)
  • Figure 41. Global Autoimmune Disease Therapeutics: by Distribution Channel USD Million (2021-2026)
  • Figure 42. Global Autoimmune Disease Therapeutics: by Drug Class USD Million (2021-2026)
  • Figure 43. South America Autoimmune Disease Therapeutics Share (%), by Country
  • Figure 44. Asia Pacific Autoimmune Disease Therapeutics Share (%), by Country
  • Figure 45. Europe Autoimmune Disease Therapeutics Share (%), by Country
  • Figure 46. MEA Autoimmune Disease Therapeutics Share (%), by Country
  • Figure 47. North America Autoimmune Disease Therapeutics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Amgen Inc. (United States)
  • Genentech Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Pfizer Inc. (United States)
  • Novartis International AG (Switzerland)
  • Merck & Co. Inc. (United States)
  • Bayer Schering Pharma AG (Germany)
  • Johnson & Johnson Inc. (United States)
  • Parvus Therapeutics Inc (United States)
  • Biogen Idec Inc. (United States)
  • Sanofi S.A (France)
Additional players considered in the study are as follows:
Elan Corporation Plc (Ireland) , Eli Lilly and Company (United States) , Chugai Pharmaceutical Co. Ltd. (Japan) , GlaxoSmithKline Plc (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation